Why the study?
Do GPIIb/IIIa inhibitors reduce ischemic events in patients undergoing angioplasty or with unstable angina?
Population
Patients undergoing angioplasty and patients with unstable angina who are candidates for PTCA within 24 hours
Design
Review
Authors
Loading...
May support GPIIb/IIIa use in angioplasty; leaves open need for RCTs confirming net benefit today.
Do GPIIb/IIIa inhibitors reduce ischemic events in patients undergoing angioplasty or with unstable angina?
GPIIb/IIIa inhibitors represent a promising class of antiplatelet agents for reducing ischemic complications during percutaneous coronary interventions.
Coller et al. (2009) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: